Bob Libbey

Corporate communications leader and experienced writing coach. You are what you write. Keep it simple. Keep it real.

[BeOne Medicines @BeOneMedicines]

Our flagship manufacturing and clinical R&D facility, opening next week in Hopewell, N.J., will help us scale production of our innovative medicines and portfolio in the future to better serve patients around the world. Learn more in this @axios article. https://t.co/Mp4HKQ5eHx

[Bob Libbey @bob_libbey]

Another exciting day of growth and progress for @BeiGeneGlobal !

[BeOne Medicines @BeOneMedicines]

The last piece of structural steel was laid at our Hopewell, NJ campus today, opening a new phase of construction as we expand our U.S. manufacturing and R&D footprint. The facility is expected to be completed next year. https://t.co/ppmJ4Y5HoX

[Bob Libbey @bob_libbey]

Great news for @BeiGeneGlobal and #patients.

[BeOne Medicines @BeOneMedicines]

Based on results from two global Phase 3 trials, our novel BTK inhibitor has received approval from the U.S. FDA for use in adults with chronic lymphocytic leukemia (#CLL) or small lymphocytic leukemia (#SLL). https://t.co/Hb2D0BPgsb

[John V. Oyler @johnvoyler]

We’re dedicated to following the science at BeiGene, and these final PFS results from our ALPINE trial strengthen our belief that our BTKi can be a practice-changing treatment option for patients with chronic lymphocytic leukemia (#CLL).

[BeOne Medicines @BeOneMedicines]

The final progression-free survival (PFS) analysis of our ALPINE trial has been published in @NEJM and we're presenting the data today in a late-breaking session at #ASH22. https://t.co/buQhszwtDP

[Bob Libbey @bob_libbey]

Great event, glad to have joined w/my committed @BeiGeneGlobal colleagues! #cancerhasnoborders

[BeOne Medicines @BeOneMedicines]

Tonight's the night, Boston! Join us tonight at the @LLSusa Light The Night walk as we raise awareness and support for those battling blood cancers. Let's shine a ray of hope. https://t.co/DqceuQyAX5

[Bob Libbey @bob_libbey]

Absolutely!

[John V. Oyler @johnvoyler]

At @BeiGeneGlobal, how we work is as important as the work we do. Our values guide us in working with an absolute commitment to ethics, integrity, and compliance. https://t.co/Ow4vKhXC8Q

[BeOne Medicines @BeOneMedicines]

Our BTK inhibitor is now approved in El Salvador for the treatment of three rare blood cancers. Each new approval means our innovative medicines can reach more patients who need them.

[BeOne Medicines @BeOneMedicines]

The “all-out war” we’re waging is against the common global enemy of cancer, a heartbreaking diagnosis affecting millions around the world, spanning all backgrounds and geographies. Our collective fight is against this dreaded disease; we won’t stop until we prevail.

[Bob Libbey @bob_libbey]

#cancerhasnoborders

[John V. Oyler @johnvoyler]

At @BeiGeneGlobal, we’ve built an extensive array of novel #cancer models to help us better select targets. These advanced models help us evaluate drug candidates in conditions that mimic cancer at the time of treatment. https://t.co/UiMwRaPJuc

[Bob Libbey @bob_libbey]

Good luck, @crileyCSR!

[BeOne Medicines @BeOneMedicines]

We're committed to an equitable and sustainable future through our #ESG goals. Christine Riley Miller, our global head of ESG, will discuss trends tomorrow at the Association of Corporate Citizenship Professionals Virtual Conference. https://t.co/7O67sYbZ3Q

[Bob Libbey @bob_libbey]

Congratulations, @johnvoyler, on the well deserved honor.

[BeOne Medicines @BeOneMedicines]

Our Co-Founder, Chairman and CEO @johnvoyler has been named to this year's @PharmaVoice 100. The list recognizes leaders who are a driving force in the life sciences industry and have a positive impact through their actions. https://t.co/MhLkICqjzr

[John V. Oyler @johnvoyler]

At @BeiGeneGlobal, we’re fortunate to attract the industry’s top talent – colleagues who are motivated to transform the biotech industry. Meet a few of our people who bring our vision to life. https://t.co/Yt3fQuu9YO

[John V. Oyler @johnvoyler]

When leaders give their people more autonomy, performance and loyalty improve. This @Forbes article suggests three strategies to offer autonomy and support strong, empowered teams. https://t.co/RPLE7zmbx3

[Bob Libbey @bob_libbey]

Well deserved, Shreya, congrats!

[BeOne Medicines @BeOneMedicines]

Congratulations to Shreya Jani, who’s been promoted to SVP, Corporate Affairs (ex-Greater China), responsible for #patientadvocacy & #publichealth policy; #ESG; leadership, colleague & #digital communications; & external affairs.

[Bob Libbey @bob_libbey]

Thanks, Jim! #PrideMonth

[BeOne Medicines @BeOneMedicines]

As #PrideMonth comes to a close, we remain committed to fostering an inclusive environment where individual differences are respected.

[BeOne Medicines @BeOneMedicines]

#Juneteenth is a celebration of freedom & a chance to honor Black culture & history in the U.S. Our Inclusion, Diversity, Equity, & Awareness (IDEA) Council marked the occasion by sharing perspectives from historians reflecting on the meaning of the day.

[Bob Libbey @bob_libbey]

#milestone

[BeOne Medicines @BeOneMedicines]

Our BTK inhibitor is now approved in Kuwait, Bahrain and Qatar for adult patients with previously treated mantle cell lymphoma (MCL), marking 50 countries and regions where it’s available to patients. https://t.co/SFsxnljgN5

[BeOne Medicines @BeOneMedicines]

We’re proud to be founding partners in the Access to Oncology Medicines (ATOM) Coalition, working with @uicc and other highly respected organizations worldwide to improve access to #cancer medicines in low- and lower-middle-income countries. https://t.co/429SOKAXsX

[Bob Libbey @bob_libbey]

#cancerhasnoborders

[BeOne Medicines @BeOneMedicines]

May is National #Cancer Research Month, a time to celebrate the many ways our 8,400+ colleagues support the ongoing, global fight against cancer. https://t.co/IItq57LgCJ #ResearchSavesLives #NCRM22 #cancerhasnoborders